EyePoint

EyePoint Net Income

The Net Income of EyePoint (EYPT) as of Oct 16, 2026 is -231.96 M USD. In the previous year, Net Income was -130.87 M USD — a change of 77.25% (lower).

Net Income

-231.96 MUSD

YoY

77.25%

Last updated:

In 2025, EyePoint's profit amounted to -231.96 M USD, a 77.25% increase from the -130.87 M USD profit recorded in the previous year.

The EyePoint Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Income
Date
Net Income
Jan 1, 2023
-70.80 M USD
Jan 1, 2024
-130.87 M USD
Jan 1, 2025
-231.96 M USD
Jan 1, 2026 (e)
-209.36 M USD
Jan 1, 2027 (e)
-153.54 M USD
Jan 1, 2028 (e)
-91.82 M USD
Jan 1, 2029 (e)
6.12 M USD
Jan 1, 2030 (e)
73.40 M USD
The EyePoint Net Income history
YEARNet IncomeYoY
est73.40 MUSD+1,098.85%
est6.12 MUSD-106.67%
est-91.82 MUSD-40.19%
est-153.54 MUSD-26.66%
est-209.36 MUSD-9.75%
-231.96 MUSD+77.25%
-130.87 MUSD+84.86%
-70.80 MUSD-30.77%
-102.25 MUSD+75.04%
-58.42 MUSD+28.69%
-45.39 MUSD-20.07%
-56.79 MUSD+6.81%
-53.17 MUSD+187.64%
-18.49 MUSD-14.21%
-21.55 MUSD-439.48%
6.35 MUSD-147.53%
-13.36 MUSD+12.23%
-11.90 MUSD-52.08%
-24.84 MUSD+187.84%
-8.63 MUSD-198.57%
8.75 MUSD-448.59%
-2.51 MUSD-96.68%
-75.67 MUSD-27.01%
-103.68 MUSD+395.74%
-20.91 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

EyePoint Revenue

EyePoint Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
46.02 M USD
-75.07 M USD
-70.80 M USD
Jan 1, 2024
43.27 M USD
-145.85 M USD
-130.87 M USD
Jan 1, 2025
31.37 M USD
-243.43 M USD
-231.96 M USD
Jan 1, 2026 (e)
1.72 M USD
-259.56 M USD
-209.36 M USD
Jan 1, 2027 (e)
17.93 M USD
-262.07 M USD
-153.54 M USD
Jan 1, 2028 (e)
196.31 M USD
-189.90 M USD
-91.82 M USD
Jan 1, 2029 (e)
437.38 M USD
10.50 M USD
6.12 M USD
Jan 1, 2030 (e)
621.93 M USD
121.31 M USD
73.40 M USD

EyePoint Margins

EyePoint stock margins

The EyePoint margin analysis displays the gross margin, EBIT margin, as well as the profit margin of EyePoint. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for EyePoint.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
89.93 %
-163.13 %
-153.84 %
Jan 1, 2024
91.42 %
-337.06 %
-302.43 %
Jan 1, 2025
93.41 %
-775.98 %
-739.42 %
Jan 1, 2026 (e)
93.41 %
-15,104.35 %
-12,182.78 %
Jan 1, 2027 (e)
93.41 %
-1,462.00 %
-856.53 %
Jan 1, 2028 (e)
93.41 %
-96.73 %
-46.77 %
Jan 1, 2029 (e)
93.41 %
2.40 %
1.40 %
Jan 1, 2030 (e)
93.41 %
19.51 %
11.80 %

EyePoint Stock analysis

What does EyePoint do? EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and marketing of innovative products targeting medical and eye-related conditions. The company was founded in 1987 and is headquartered in Watertown, Massachusetts. EyePoint Pharmaceuticals has a diverse portfolio of products focused on the treatment of eye diseases. This includes products for the treatment of retinal diseases such as diabetic retinopathy, macular degeneration, and retinal vein occlusions, as well as products for preventing postoperative infections and relieving pain after eye surgeries. The business model of EyePoint Pharmaceuticals is based on the development and marketing of drugs and technologies tailored to the needs of patients and physicians in the field of ophthalmology. The company aims to improve patients' quality of life by offering innovative, safe, and effective products of the highest quality. One of EyePoint Pharmaceuticals' key technologies is the Durasert technology, which allows for controlled release of drugs over an extended period of time. This technology is utilized in many of the company's products, such as the Iluvien implant for treating diabetic retinopathy and macular degeneration. The company operates in various sectors, including ophthalmology, pain management, and ophthalmology. Each of these sectors has its own products and technologies tailored specifically to the needs of patients and physicians in those areas. A significant factor in EyePoint Pharmaceuticals' business model is partnerships with other companies and organizations that support collaboration in the development and marketing of new products. One such partnership is the joint venture with Ocumension Therapeutics, which aims to market EyePoint Pharmaceuticals' products in the Asian market. Overall, the company has introduced a variety of innovative products to the market that have had a significant impact on ophthalmology. These include products such as the Ozurdex implant for treating macular degeneration and uveitis, as well as the Dexycu injection for preventing postoperative inflammation and pain. In recent years, the company has made progress in the development of drugs for retinal diseases such as diabetic retinopathy and retinal vein occlusions. One such development is the Yutiq implant, specifically designed to slow the progression of diabetic retinopathy. Overall, EyePoint Pharmaceuticals has a significant influence on ophthalmology and plays a crucial role in the development of innovative products and technologies to improve patients' quality of life. The company will continue to play an important role in the medical industry by focusing on the development and marketing of products targeting specific needs of patients and physicians in the field of ophthalmology. EyePoint is one of the most popular companies on Eulerpool.

Net Income Details

Understanding EyePoint's Profit Margins

The profit margins of EyePoint represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of EyePoint's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating EyePoint's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

EyePoint's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When EyePoint’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about EyePoint stock

Net Income of EyePoint is -231.96 M USD in 2025.

Net Income of EyePoint changed from -130.87 M USD to -231.96 M USD, representing a 77.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Income EyePoint since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's EyePoint historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — EyePoint

All Key Metrics — EyePoint